selpercatinib RET-altered
Selected indexed studies
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. (N Engl J Med, 2020) [PMID:32846061]
- Selpercatinib Aimed at RET-Altered Cancers. (N Engl J Med, 2020) [PMID:32846067]
- Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors. (Expert Rev Anticancer Ther, 2023) [PMID:37795873]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. (2022) pubmed
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. (2020) pubmed
- Selpercatinib Aimed at RET-Altered Cancers. (2020) pubmed
- Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors. (2023) pubmed
- Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA. (2021) pubmed
- Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. (2023) pubmed
- Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. (2024) pubmed
- Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis. (2024) pubmed
- RET kinase inhibitors for RET-altered thyroid cancers. (2022) pubmed
- [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer]. (2021) pubmed